Patients’ view of the heterogeneity of CLL
| Question . | N . | Yes (%) . | No (%) . | Not sure (%) . |
|---|---|---|---|---|
| Do you know about the different risk groups of patients with CLL? | 377 | 149 (40) | 141 (37) | 87 (23) |
| In the educational courses∗, did you receive any information to help you understand the different risk groups of patients with CLL? | 320 | 84 (26) | 194 (61) | 42 (13) |
| Do you know about any laboratory tests to identify each patient’s risk level? | 312 | 109 (35) | 166 (53) | 37 (12) |
| Do you know about any treatment differences between the different CLL risk groups? | 328 | 86 (26) | 160 (49) | 82 (25) |
| Do you agree all patients should be tested to identify patients at high risk? | 373 | 261 (70) | 29 (8) | 82 (22) |
| Are you a patient at high risk? | 304 | 56 (18) | 91 (30) | 157 (52) |
| Question . | N . | Yes (%) . | No (%) . | Not sure (%) . |
|---|---|---|---|---|
| Do you know about the different risk groups of patients with CLL? | 377 | 149 (40) | 141 (37) | 87 (23) |
| In the educational courses∗, did you receive any information to help you understand the different risk groups of patients with CLL? | 320 | 84 (26) | 194 (61) | 42 (13) |
| Do you know about any laboratory tests to identify each patient’s risk level? | 312 | 109 (35) | 166 (53) | 37 (12) |
| Do you know about any treatment differences between the different CLL risk groups? | 328 | 86 (26) | 160 (49) | 82 (25) |
| Do you agree all patients should be tested to identify patients at high risk? | 373 | 261 (70) | 29 (8) | 82 (22) |
| Are you a patient at high risk? | 304 | 56 (18) | 91 (30) | 157 (52) |
| . | . | Fixed (%) . | Until progression (%) . |
|---|---|---|---|
| If you were a patient with CLL at high risk, what would you prefer as a duration of the treatment? | 270 | 185 (69) | 85 (31) |
| . | . | Fixed (%) . | Until progression (%) . |
|---|---|---|---|
| If you were a patient with CLL at high risk, what would you prefer as a duration of the treatment? | 270 | 185 (69) | 85 (31) |
| . | . | Oral (%) . | Intravenous (%) . |
|---|---|---|---|
| If you were a patient with CLL at high risk, what would you prefer for administration? | 296 | 232 (78) | 64 (22) |
| . | . | Oral (%) . | Intravenous (%) . |
|---|---|---|---|
| If you were a patient with CLL at high risk, what would you prefer for administration? | 296 | 232 (78) | 64 (22) |
| . | . | Outpatient (%) . | Inpatient (%) . |
|---|---|---|---|
| If you were a patient with CLL at high risk, what would you prefer for convenience? | 283 | 257 (91) | 26 (9) |
| . | . | Outpatient (%) . | Inpatient (%) . |
|---|---|---|---|
| If you were a patient with CLL at high risk, what would you prefer for convenience? | 283 | 257 (91) | 26 (9) |
| . | . | All patients incl. high-risk (%) . | All patients excl. high-risk (%) . | None (%) . | Not sure (%) . |
|---|---|---|---|---|---|
| Should immunochemotherapy still be offered to patients at high risk (or to all patients)? | 357 | 86 (24) | 26 (7) | 22 (6) | 223 (62) |
| . | . | All patients incl. high-risk (%) . | All patients excl. high-risk (%) . | None (%) . | Not sure (%) . |
|---|---|---|---|---|---|
| Should immunochemotherapy still be offered to patients at high risk (or to all patients)? | 357 | 86 (24) | 26 (7) | 22 (6) | 223 (62) |
| . | . | Chemoimmunotherapy (%) . | New targeted agents (%) . | No preference (%) . | Discuss with physician first (%) . |
|---|---|---|---|---|---|
| What treatment would you like to receive if you were a patient at high risk? (>1 answer permitted) | 350 | 38 (11) | 57 (16) | 170 (49) | 133 (38) |
| . | . | Chemoimmunotherapy (%) . | New targeted agents (%) . | No preference (%) . | Discuss with physician first (%) . |
|---|---|---|---|---|---|
| What treatment would you like to receive if you were a patient at high risk? (>1 answer permitted) | 350 | 38 (11) | 57 (16) | 170 (49) | 133 (38) |
Educational course were not defined for survey respondents, and therefore subject to individual interpretation.